Meropenem-clavulanic acid shows activity against Mycobacterium tuberculosis in vivo.
Antimicrob Agents Chemother
; 56(6): 3384-7, 2012 Jun.
Article
en En
| MEDLINE
| ID: mdl-22450968
ABSTRACT
The carbapenems imipenem and meropenem in combination with clavulanic acid reduced the bacterial burden in Mycobacterium tuberculosis-infected macrophages by 2 logs over 6 days. Despite poor stability in solution and a short half-life in rodents, treatment of chronically infected mice revealed significant reductions of bacterial burden in the lungs and spleens. Our results show that meropenem has activity in two in vivo systems, but stability and pharmacokinetics of long-term administration will offer significant challenges to clinical evaluation.
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Tienamicinas
/
Ácido Clavulánico
/
Antibacterianos
/
Mycobacterium tuberculosis
Límite:
Animals
Idioma:
En
Año:
2012
Tipo del documento:
Article